Episode Details

IDEXX Laboratories, Inc. (IDXX) Q2 2026 — Reported August 4, 2026 BEFORE the US open for Q2 2026 (the quarter ended June 30, 2026). Revenue $1,216.6M, +9.7% reported and +9.0% organic, vs a ~$1.20B consensus. Diluted EPS $4.27, +17.6%, vs a $3.96 consensus - but $0.14 of that came from share-based-compensation tax benefits and $0.06 from currency. Gross margin 64.0% (+140bps reported, +120bps comparable); operating margin 35.0% (+140bps reported, +110bps comparable). CAG revenue $1,118.2M (+9.4%), CAG Diagnostics recurring revenue $974.7M (+11.0% reported, +10.3% organic), Water $58.6M (+14.8%), LPD $35.2M (+10.8%). Full-year 2026 guidance RAISED: revenue $4,700-4,745M (organic growth 8.5-9.7%, up from 7.7-9.7%), operating margin 32.3-32.5%, EPS $14.69-14.94 (from $14.45-14.90). Shares closed the prior regular session at $567.84 (+1.57%) BEFORE the release; the reaction session had not closed when this episode was recorded, with IDXX trading up roughly 3.5% in the pre-market. The stock is 26% below its $766.68 closing high of November 25, 2025 and 8% above its $526.44 closing low of June 30, 2026, and sits below its $620.50 two-hundred-day average. The fact that makes this quarter interesting: US same-store veterinary clinical visits have been FALLING for about three years - roughly -1.9% across 2025 and about -1% in Q1 2026 - yet IDEXX's US CAG Diagnostics recurring revenue grew 9.7% organically to $630.5M. That is an ~11 percentage point gap between the end market's foot traffic and this company's revenue, and the whole investment case lives inside it. We went looking for the obvious explanation - that it is just price - and the evidence says mostly NOT: VetLab consumables grew 13.6% organically on stated VOLUME gains and an 11% larger global premium instrument installed base, and reference lab grew 10.3% organically on higher testing volumes and net new customers. Only rapid assay, at +1.1%, is a price story - and that one is self-inflicted, with volumes cannibalised by IDEXX's own Catalyst Pancreatic Lipase test. Two more things almost nobody flagged. FIRST, the $0.31 EPS beat is really about $0.11 of operations: $0.14 was share-comp tax benefits and $0.06 currency, both disclosed in the release. SECOND, forward free cash flow is LOWER than trailing free cash flow - capex steps from ~$117M trailing to a guided ~$180M, which is why the company guides FCF to 90-100% of net income against the 110% it just delivered. THE CALL: AVOID (3/5, AN ELITE BUSINESS AT A PRICE THAT NEEDS PERFECTION) — base-case value ~$465.0 vs ~$567.84 today. KEY METRICS: - CALL: AVOID 3/5 - fair value ~$465 vs the $567.84 close (about -18%), and below the LOWEST price target on Wall Street ($620). This is NOT a criticism of the business, which is outstanding; it is a call on the price of entry. Base free cash flow is taken from the company's OWN guidance rather than from trailing results: FY2026 EPS of $14.82 at midpoint on ~79.4M shares is ~$1,176M of net income, and IDEXX guides FCF to 90-100% of net income = ~$1,117M. Grow that 11% a year for five years (ABOVE the 8.5-9.7% organic revenue guide, crediting 70-90bps of annual margin expansion plus a 1.5-2% buyback), then 7% for five more, then 3% forever, discounted at 8%: PV of 2027-2036 FCF $12,303M + PV of terminal value $25,201M = enterprise value $37,503M, less $772M net debt = $36,731M equity / 78.95M shares = ~$465. Bear $343, bull $590; probability-weighted 25/50/25 = ~$478. - REVERSE DCF - THE WHOLE ARGUMENT: at $567.84 the market capitalisation is ~$44.8B and enterprise value ~$45.6B - 40.8x FY2026E free cash flow of $1,117M, a 2.5% FCF yield, and 38.3x guided FY2026 EPS. To justify that at an 8% discount rate you need roughly 14% free cash flow growth for five years and then 10%. IDEXX itself guides 8.5-9.7% ORGANIC REVENUE growth and 12-14% EPS growth - and that EPS figure already contains 1.5-2% of share-count reduction. The market is therefore pricing an acceleration above what the comp